• Home
  •  / Generex Biotechnology

Generex Biotechnology

OverviewSuggest Edit

Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.        

TypePublic
HQBurlington, CAMap
Websitegenerex.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2018)3(-50%)
Revenue (FY, 2018)$703.2 K
Share Price (Oct 2017)$2.6 (-3%)

Generex Biotechnology Office Locations

Generex Biotechnology has an office in Burlington
Burlington, CA (HQ)
4145 N Service Rd
Show all (1)

Generex Biotechnology Financials and Metrics

Generex Biotechnology Revenue

Generex Biotechnology's revenue was reported to be $703.24 k in FY, 2018
USD

Revenue (Q3, 2019)

1.1m

Gross profit (Q3, 2019)

(172.0k)

Gross profit margin (Q3, 2019), %

(15.7%)

Net income (Q3, 2019)

(11.2m)

EBIT (Q3, 2019)

(9.3m)

Market capitalization (31-Oct-2017)

3.1m

Closing stock price (31-Oct-2017)

2.6

Cash (30-Apr-2019)

1.4m
Generex Biotechnology's current market capitalization is $3.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

703.2k

General and administrative expense

3.0m2.7m1.4m1.2m2.4m

R&D expense

1.4m1.2m467.4k422.3k839.1k

Operating expense total

4.4m3.9m1.9m1.6m3.2m
Quarterly
USDQ3, 2014Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

2.2k700.0k702.2k1.7m3.4m1.1m

Cost of goods sold

870.6k2.0m1.3m

Gross profit

848.5k1.4m(172.0k)

Gross profit Margin, %

49%42%(16%)
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.3m750.0k16.9k2.9m1.0m

Accounts Receivable

980.033.6k

Inventories

10.0k12.1k

Current Assets

3.5m801.2k25.0k2.9m1.2m
Quarterly
USDQ3, 2014Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

4.2m52.4k31.8k47.2k37.1k2.3m2.0m1.6m2.4m2.4m1.4m

Accounts Receivable

175.0175.03.0m2.3m1.8m

Inventories

22.7k12.0k12.0k12.0k838.7k1.1m250.0k

Current Assets

4.3m104.4k36.9k55.3k4.1m2.6m2.3m1.7m6.4m6.1m3.7m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.4k)(2.2m)(3.2m)35.9m

Depreciation and Amortization

368.4k380.7k265.2k5.0k23.8k

Inventories

11.1k(2.0k)

Accounts Payable

(490.4k)(117.7k)1.1m899.8k872.2k
Quarterly
USDQ3, 2014Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(2.4m)27.5m17.7m21.1m17.8m5.4m(5.8m)

Depreciation and Amortization

280.7k52.7k123.1k194.2k2.3k1.2k2.0k17.5k25.7k378.2k550.3k

Inventories

(1.6k)(2.0k)(2.0k)(2.0k)242.2k386.0k1.2m

Accounts Payable

(300.4k)522.1k662.8k823.7k592.6k318.0k211.7k673.9k1.0m3.3m7.1m
show all
USDY, 2019

Financial Leverage

3.9 x
Show all financial metrics

Generex Biotechnology Online and Social Media Presence

Generex Biotechnology's Trends

Embed Graph

Generex Biotechnology News and Updates

October 10, 2019

Generex Biotechnology Announces that Excellagen® Inventor, Dr. Lois Chandler will Present Clinical Data on Rapid Healing of Diabetic Foot Ulcers at The Symposium on Advanced Wound Care (SAWC) Fall Meeting

MIRAMAR, Fla., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased and proud to announce that Dr. Lois Chandler, inventor of Excellagen and an advisor to our subsidiary, Olaregen Therapeutix, will be presenting the poster entitled “Wound Conforming Matrix Co…
September 30, 2019

Generex Biotechnology Subsidiary Olaregen Therapeutix Signs National Sales & Distribution Agreement With AvKare Medical to Distribute Excellagen® Throughout the VA Hospital System

MIRAMAR, Fla., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has entered into a national sales and distribution agreement with AvKare Inc. to be…
September 03, 2019

Generex Biotechnology Confirms Record Date for 1:1 Dividend

MIRAMAR, Fla., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today confirmed that the record date for the 1:1 (100%) stock dividend was recorded on August 30, 2019, and the dividend will be paid on October 29th  to all shareholders who hold their shares through …
August 16, 2019

Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic

MIRAMAR, Fla., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology (www.generex.com) (OTCQB:GNBT) today announced that the Company has identified a public, development stage company that is fully reporting and current on its filings with the SEC, and DTC eligible that will serve as a vehicle f…
August 12, 2019

Generex Biotechnology Announces Update to the Previously Declared 1:1 Stock Dividend

MIRAMAR, Fla., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that it was proceeding with the dividend in anticipation of listing on Nasdaq. Therefore, Generex plans to reward Generex’s loyal shareholders by announcing…
July 29, 2019

Generex Biotechnology Provides Guidance on 1:1 Stock Dividend

MIRAMAR, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today provided guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders.
Show more

 Generex Biotechnology Frequently Asked Questions

  • How many employees does Generex Biotechnology have?

    Generex Biotechnology has 3 employees.

  • What is Generex Biotechnology revenue?

    Latest Generex Biotechnology annual revenue is $703.2 k.

  • What is Generex Biotechnology revenue per employee?

    Latest Generex Biotechnology revenue per employee is $234.4 k.

  • Who are Generex Biotechnology competitors?

    Competitors of Generex Biotechnology include Vitality Biopharma, Opiant Pharmaceuticals and Mylan.

  • Where is Generex Biotechnology headquarters?

    Generex Biotechnology headquarters is located at 4145 N Service Rd, Burlington.

  • Where are Generex Biotechnology offices?

    Generex Biotechnology has an office in Burlington.

  • How many offices does Generex Biotechnology have?

    Generex Biotechnology has 1 office.